



Kelly Brewer, Ph.D.


Patent Agent

Boston Office

155 Seaport Blvd., Boston, MA 02210

978.202.3446

Kelly.Brewer@hbsr.com



PRACTICE AREAS

- Patents
- Post-Grant Proceedings

TECHNOLOGIES

- Biotechnology & Life Sciences
- Biologics & Immunotherapies
- Bioinformatics

EDUCATION

- B.S. in Biology and German Studies, Brigham Young University
- Ph.D. in Biomedical Science (Genetics and Developmental Biology), University of Connecticut Health Center

Kelly Brewer assists with patent preparation and prosecution in the areas of biotechnology, life sciences, biologics, immunotherapies, and bioinformatics.

Kelly's diverse scientific experience spans the fields of cancer biology, genetics, genomics, endocrinology, bioinformatics, molecular biology, biophysics, and immunology. Kelly earned her Ph.D. in Biomedical Science with a concentration in Genetics and Developmental Biology from the University of Connecticut. Her dissertation research at the University of Connecticut Health Center focused on the molecular drivers of parathyroid tumorigenesis and utilized patient samples, transgenic mouse models, and genome-edited human embryonic stem cells to identify and characterize candidate oncogenes and tumor suppressor genes. Kelly's research experience also includes investigating tumor microenvironment and metastatic potential in lung adenocarcinoma at Yale School of Medicine; assisting investigators in the Harvard-affiliated hospital and research institute community with flow cytometry at Dana-Farber Cancer Institute; and studying the properties of apoptotic mammalian cell membranes at Brigham Young University Cancer Research Center.

Kelly has co-authored scientific articles that have appeared in *Endocrine Connections*, *Endocrine-Related Cancer*, *Cancer Research*, and *Biochimica et Biophysica Acta—Biomembranes*. She has also presented research at the national and international scientific society meetings of the American Association for Cancer Research, American Society of Human Genetics, Endocrine Society, and WorldMEN (Multiple Endocrine Neoplasia).

IP NEWS ALERTS

- United States Patent and Trademark Office Releases New Guidelines for Assessing Enablement in View of Amgen v. Sanofi, February 2024